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Recent reports demonstrated that neovasculature of certain murine tumours inhibits migration of lymphocytes to malignant tissues.
We examined the possible existence of this phenomenon in human prostate adenocarcinoma by relating extent, patterns and
composition of leucocyte infiltrates in adenocarinoma specimens (N¼28) to microvessel density and percentages of these vessels
expressing adhesion molecules CD54, CD106 and CD62E. Specimens of nodular hyperplasia (N¼30) were used as a control for
nonmalignant prostate. Increased microvessel density was detected in foci of adenocarcinoma, as compared with adjacent benign
areas (P¼0.004) or hyperplastic specimens (P¼0.001). Only CD54 was detected on prostate vasculature; percentages of CD54-
expressing vessels in adenocarcinoma lesions and adjacent areas were higher than in hyperplasia (P¼0.041 and P¼0.014,
respectively). Infiltrating leucocytes were either scattered diffusely in tissue or organised into clusters mainly composed of CD4-
positive lymphocytes; smaller percentage of tissue was occupied by clustered infiltrates in adenocarcinoma foci (mean¼0.7;
median¼0; range¼0–5) than in adjacent tissue (mean¼2.5; median¼1; range¼0–15; P¼.021) and hyperplasia (mean¼1.9;
median¼2; range¼0–5; P¼.006). In adenocarcinoma foci, microvessel density tended to negatively correlate with percentage of
tissue occupied by an overall leucocyte infiltrate (mean¼8.6; median¼7.5; range¼30) and negatively correlated with percentage
of tissue occupied by clustered infiltrate (P¼0.045). Percentage of CD54-expressing vessels positively correlated with percentage of
tissue occupied by an overall (mean¼12; median¼10; range¼30; P¼0.01) and clustered (P¼0.023) infiltrate in hyperplasia,
whereas in carcinoma-adjacent benign areas, correlation was detected only for clustered infiltrates (P¼0.02). The results indicate that
impaired access of lymphocytes to malignant lesions is associated with increased numbers of newly formed blood vessels, whereas
vascular CD54 likely contributes to extravasation of lymphocytes only in benign prostate tissue.
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Although many types of malignancies are potentially antigenic and
immunogenic (Romero et al, 1998; Lee et al, 1999; Campoli et al,
2005), immune-effector cells recognising tumour-specific antigens
fail to reject the tumour, when grafted into the host circulation
(Pre ´vost-Bondel et al 1998; Romero et al, 1998; Lee et al, 1999).
Neoangiogenesis is an integral part of tumour progression, where a
vasculature in primary neoplastic lesion undergoes ‘angiogenic
switch’ and converts into a chaotic network of rapidly proliferating
blood vessels displaying marked structural and molecular
abnormalities (Bono et al, 2002; Ryschich et al, 2002; Strohmeyer
et al, 2004; Ozawa et al, 2005). Studies employing experimental
murine tumour microcirculation models and intravital fluorescent
microscopy techniques demonstrated impaired interactions
between circulating leucocytes and endothelial cells, thus implying
the existence of a barrier function in tumour-associated blood
vessels (Ryschich et al, 2002; Dirkx et al, 2003; Garbi et al, 2004).
Of particular interest are reports explaining the ‘barrier’ effect of
tumour neovasculature by diminished expression of cytoadherence
molecules (CAMs) on endothelial lining of blood vessels (Tromp
et al, 2002; Dirkx et al, 2003, 2006; Bouma-ter Steege et al, 2004;
Baluk et al, 2005). For example, more intense infiltration of
malignant lesions by lymphocytes was observed in specimens
of medullary breast carcinoma displaying elevated expression of
CD54 (ICAM-1) and CD106 (VCAM-1) as compared with ductal
breast carcinoma displaying diminished expression of these CAMs
(Bouma-ter Steege et al, 2004). Correspondingly, the experiments
on tumour-bearing mice demonstrated upregulation of vascular
CAMs expression following angiostatic therapy or of T-cell therapy
combined with trigger of inflammation, which was accompanied
by intense infiltration of malignant lesions by lymphocytes and
reduction of tumour size (Garbi et al, 2004; Dirkx et al, 2006).
Despite the obvious attractiveness of mode of tumour-immune
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sevasion, it cannot be automatically applied to all types of murine
and human malignancies because of marked differences between
vascular beds in distinct anatomic locations (Essler and Ruoslahti,
2002).
The incidence of prostate carcinoma is increasing steadily and
no efficient curative approaches are currently available. In course
of this disease, the numbers of newly formed microvessels
progressively increase (Montironi et al, 1993; Mazzucchelli et al,
2000; Bono et al, 2002; Strohmeyer et al, 2004; Ozawa et al, 2005).
However, it is not known whether these neovessels may attenuate
migration of lymphocytes to malignant lesions and if so, whether
vascular CAMs are involved. We address this issue by relating
microvessel density (MVD) and percentages of these vessels
expressing major CAMs to the extent and patterns of leucocyte
infiltrate in specimens of human prostate adenocarcinoma.
Because nodular hyperplasia of the prostate gland (NHPG) is a
common histopathological finding in males of this age group and
hyperplastic changes were also detected in perimalignant benign
areas of carcinoma specimens, tissue specimens affected by NHPG
were used as a control for the prostate gland not affected by the
malignant disease.
MATERIALS AND METHODS
Tissue specimens
A series of 28 prostate adenocarcinoma specimens obtained by
radical prostatectomy and 30 NHPG specimens obtained by
transurethral resection were available from the Institute of
Pathology, Soroka University Medical Center. Gleason score values
for carcinomas were 5 in one out of 28 cases, 6 in four out of 28
cases, 7 in 17 out of 28 cases, 8 in four out of 28 cases and 9 in
two out of 28 cases. All tumours were of Stage II T1c–T2 N0 M0.T h e
mean age of carcinoma patients was 64 years, mean age of NHPG
patients was 71 years. All examinations employing specimens
obtained from patients were approved by the institutional Helsinki
Committee and were carried out according to the Israeli law.
Immunohistochemistry, estimation of MVD and
assessment of infiltrate
Sections of prostate tissue were reacted to commercial antibodies
diluted, as follows: monoclonal anti-CD34 (Dako Cytomation A/S,
Glosstrop, Denmark), diluted 1:100; monoclonal anti-CD54
(Zymed Laboratories Inc., South San Francisco, CA, USA) ready
to use; monoclonal anti-CD106 (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA), diluted 1:25 and 1:50; monoclonal anti-
CD106 (Dako Cytomation), diluted 1:25; monoclonal CD62E
(Santa Cruz), diluted 1:25; monoclonal antiinterleukin (IL)-10
(R&D Systems Europe Ltd, Abington, UK), diluted 1:20; mono-
clonal anti-CD45 (Dako Cytomation), diluted 1:100; anti-CD3
(Dako Cytomation), diluted 1:100; anti-CD4 (Zymed) ready to use;
anti-CD8 (Dako Cytomation), diluted 1:25; anti-CD20 (Dako
Cytomation), diluted 1:100; anti-CD14 (Zymed), diluted 1:50; and
anti-CD15 (Dako Cytomation), diluted 1:50. Antigen retrieval
procedures included boiling for 20min in 20mmol citrate buffer
solution (pH 6) (for anti-CD34, anti-CD45, anti-CD3, anti-CD4,
anti-CD8, anti-CD20, anti-CD15 anti-IL-10 antibodies), boiling for
20min in a Tris–EDTA buffer (10mmol Tris base, 1mmol EDTA
and 0.05% Tween 20 (pH 9)) (for anti-CD106 antibodies), 0.15%
trypsin in water (pH 7.8) for 20min at 371C (for anti-CD14
antibodies). Sections of human tonsils were used as positive
controls for the aforementioned antibodies. To estimate MVD,
specimens were screened at  200 magnification to detect areas
enriched with blood vessels (‘hot spots’). Microvessel density was
assessed in three ‘hot spots’ by counting blood vessels displaying
CD34 immune reactivity at  400 magnification simultaneously by
three observers (NSV, SF and ZS), using a multiple-head light
microscope and expressed as a mean of three ‘hot spots’. The
counts were assessed in a blind manner without the knowledge of
patient’s clinical course or outcome. Any single endothelial cell
or cluster of endothelial cells positively stained by anti-CD34
antibodies was considered as a microvessel. Vessels of a caliber
larger than approximately eight red blood cells were excluded from
the analysis. To attribute the expression of CAMs to microvessels,
‘hot spots’ in anti-CD34-probed sections were marked, and areas
corresponding to the marked ‘hot spots’ were found in successive
tissue sections probed with anti-CAM antibodies (only CD54 was
detected in prostate vessels) and used for counting of CD54-
expressing microvessels. The percentages of CD54-expressing
microvessels were calculated using estimated values of MVD.
The quantification of infiltrating leucocytes (assessed according to
immune reactivity to CD45 or markers of specific leucocyte
subsets) was performed at  100 magnification simultaneously by
three independent observers (SF, ZS and DF) by estimating
percentage of tissue occupied by any given component (single cells
or cluster of cells).
Statistical analysis
SPSS software was used for statistical calculations. Microvessel
density and percentages of CD54-expressing blood vessels in
carcinoma lesions were compared with those in benign perima-
lignant areas by using paired t-test. Microvessel density and
percentages of CD54-expressing blood vessels in carcinoma lesions
or perimalignant benign zones were compared with those in NHPG
by using grouped t-test. w
2 Test was used to compare IL-10
expression in carcinoma lesions, perimalignant benign areas and
NHPG. Correlations between variables were computed by using
Pearson’s correlation (r).
RESULTS
A significantly higher MVD was found in the vicinity of
adenocarcinoma lesions (PAC) (25.18þ2), as compared with
benign perimalignant regions of the same specimens (peri-PAC)
(17.7þ1.3) (P¼0.003) and specimens affected by NHPG
(17.4þ0.9) (P¼0.001), whereas no difference in MVD values
between peri-PAC and NHPG was detected (Figure 1). Among
CAMs analysed, only CD54 was expressed by the prostate
vasculature (Figure1A and data not shown). We detected higher
percentages of CD54-expressing microvessels in PAC and peri-
PAC, as compared with NHPG (P¼0.014 and P¼0.041, respec-
tively; Figure 1). It is noteworthy that CD54 was also identified on
glandular epithelium; however, only CD54-expressing blood
vessels were counted.
Most tissue-infiltrating leucocytes detected according to CD45
immune reactivity resided in periglandular stroma and only few
intraepithelial leucocytes were identified. Two distinct patterns of
infiltration were detected, that is, diffuse periglandular infiltrates
and leucocytes clustered into follicle-like aggregates (Figure 2A).
A significantly lower percentage of tissue occupied by clustered
infiltrates assessed according to CD45 immune reactivity was
found in PAC (mean (M)¼0.7; median (Mdn)¼0; range
(Rng)¼0–5; standard error mean (s.e.m.)¼0.2), as compared
with peri-PAC (M¼2.5; Mdn¼1; Rng¼0–15; s.e.m.¼0.7;
P¼0.021) and NHPG (M¼1.9; Mdn¼2; Rng¼0–5; s.e.m.¼0.3;
P¼.006) (Figure 2B), whereas no such differences among PAC,
peri-PAC and NHPG were demonstrated for percentage of tissue
occupied by an overall leucocyte infiltrate (data not shown).
Irrespective of their location (PAC, peri-PAC or NHPG), clusters
were mainly composed of CD3-positive cells (CD4-positive cells
predominated over CD8-positive cells) and less of CD20-positive
cells (Figure 3), whereas no CD14- or CD15-positive cells were
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sdetected in clusters; the latter cells were scattered in the stromal
tissue at very low numbers and not detected in most specimens
(data not shown). There was a tendency towards negative
correlation between MVD and percentage of tissue occupied by
an overall leucocyte infiltrate (diffuse and clustered) assessed
according to CD45 immune reactivity in PAC (M¼8.6, Mdn¼7.5,
Rng¼0–30, s.e.m.¼1) (r¼ 0.338, P¼0.06), whereas in peri-
PAC, a tendency towards positive correlation between MVD
and an overall leucocyte infiltrate (M¼2.9, Mdn¼2, Rng¼0–10,
s.e.m.¼0.58) was detected (r¼0.304, P¼0.085) (Table 1). Per-
centage of tissue occupied by clustered infiltrates assessed
according to CD45 and CD4 (M¼0.2, Mdn¼0, Rng¼0–1,
s.e.m.¼0.01) immune reactivity negatively correlated with
MVD in PAC (r¼ 0.362, P¼0.045 and r¼0.389, P¼0.033,
respectively); no such correlation was demonstrated in peri-PAC
and NHPG (Table 1). However, in NHPG, we detected a positive
correlation between percentages of CD54-expressing vessels and
percentage of tissue occupied by an overall leucocyte infiltrate
assessed according to CD45 (M¼12; Mdn¼10; Rng¼0–30,
s.e.m.¼1.5) and CD4 (M¼2.8; Mdn¼2; Rng¼0–5, s.e.m.¼0.3)
immune reactivity (r¼0.454, P¼0.010 and r¼0.404, P¼0.023,
respectively). CD54-expressing vessels also correlated with
percentage of tissue occupied by clustered infiltrates assessed
according to CD45 and CD4 (M¼0.9; Mdn¼1; Rng¼0–3,
s.e.m.¼0.2) immune reactivity (r¼0.409, P¼0.023 and
r¼0.397, P¼0.024, respectively) (Table 1). In peri-PAC, percen-
tages of CD54-expressing vessels correlated with percentage of
tissue occupied by clustered infiltrates assessed according to CD45
immune reactivity (r¼0.440, P¼0.020), whereas only a tendency
towards positive correlation between CD54-expressing vessels
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Figure 1 Microvessel density and percentages of CD54-expressing vessels in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and
specimens of nodular hyperplasia of the prostate gland (NHPG). (A) Typical photographs of successive tissue sections reacted to anti-CD34 and anti-CD54
antibodies (magnification  200). (B) Microvessel density and percentages of CD54-expressing vessels in PAC, peri-PAC and NHPG (meanþs.e.m.).
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Figure 2 Patterns of leucocyte infiltration in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of
the prostate gland (NHPG). (A) Tissue infiltrating leucocytes in PAC, peri-PAC and NHPG identified according to CD45 immune reactivity (magnification
 40). (B) Percentages of tissue area occupied by clustered infiltrates assessed according to CD45 immune reactivity in PAC, peri-PAC and NHPG
(meanþs.e.m.).
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sand clustered CD4 infiltrates (M¼1.1; Mdn¼0.5; Rng¼0–10,
s.e.m.¼0.5) was observed (r¼0.361, P¼0.054). Neither MVD
nor percentages of CD54-expressing vessels correlated with
leucocyte infiltrate assessed according to immune reactivity to
other leucocyte markers (CD8, CD20, CD14 and CD15) (data not
shown).
Many tumours produce inhibitory cytokines (Mantovani et al,
2004), which could alter the function of endothelium-adhered
leucocytes including their ability to extravasate. Studies performed
on murine hepatocellular carcinoma showed that impaired
migration of lymphocytes to neoplastic liver tissue coincided with
elevated production of IL-10 by endothelial cells of tumour
neovessels (Ryschich et al, 2006). In this study, we have analysed
the expression of IL-10 in 25 of 28 carcinoma specimens and in 29
of 30 NHPG specimens. Interleukin-10 was detected mostly in
glandular epithelium in PAC of 14 out of 25 of carcinoma
PAC
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Figure 3 Composition of clustered infiltrates in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia
of the prostate gland (NHPG). Successive tissue sections were reacted to antibodies recognising common (CD45) and subset-specific (CD3, CD4, CD8 – T
lymphocytes, CD20 – B lymphocytes) markers of leucocytes. Magnification  200.
Table 1 Correlations between microvessel density (MVD), percentages of CD54-expressing vessels and percentages of tissue occupied by overall and
clustered infiltrate assessed according to CD45 and CD4 immune reactivity in malignant lesions (PAC), peri-malignant benign areas (peri-PAC) and nodular
hyperplasia of the prostate gland (NHPG)
PAC Peri-PAC NHPG
CD45
total
CD45
clusters
CD4
total
CD4
clusters
CD45
total
CD45
clusters
CD4
total
CD4
clusters
CD45
total
CD45
clusters
CD4
total
CD4
clusters
MVD r¼ 0.338 r¼ 0.362* r¼ 0.159 r¼ 0.389* r¼0.304 R¼0.010 r¼0.054 r¼ 0.203 r¼ 0.136 r¼0.156 r¼ 0.122 r¼ 0.031
P¼0.06 P¼0.045 P¼0.240 P¼0.033 P¼0.085 P¼0.482 P¼0.408 P¼0.188 P¼0.253 P¼0.234 P¼0.280 P¼0.441
CD54-expressing vessels r¼0.136 r¼0.064 r¼ 0.024 r¼0.162 R¼0.202 R¼0.440* r¼ 0.062 R¼0.361 r¼0.454** R¼0.409* R¼0.404* R¼0.397*
P¼0.274 P¼0.386 P¼0.457 P¼0.230 P¼0.183 P¼0.020 P¼0.395 P¼0.054 P¼0.010 P¼0.023 P¼0.023 P¼0.024
*Correlation is significant at 0.05 level (single-tailed test is applied). **Correlation is significant at 0.01 level (single-tailed test is applied).
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sspecimens (66%), in peri-PAC of eight out of 25 of carcinoma
specimens (33%) and in NHPG of nine out of 29 of NHPG
specimens (30%) (Figure 3A and B). No statistically significant
correlations between the production of IL-10, vascular expression
of CD54 and percentage of tissue occupied by leukcocyte infiltrate
were detected (data not shown). None of parameters measured in
this study (MVD, percentage of CD54-expressing vessels, clustered
infiltrates and IL-10 production) correlated with grade of
carcinoma, serum PSA levels and patient’s age.
DISCUSSION
Neoangiogenesis is essential for supplying blood to a rapidly
growing neoplastic mass and, therefore, is an integral part of
tumour progression. Recent studies performed on experimental
murine malignancies ascribed a novel role to newly formed
tumour blood vessels, that is, inhibitory effects on proper
migration of immune-effector cells to malignant tissue (Ryschich
et al, 2002; Dirkx et al, 2003). However, the relevance of this
phenomenon for human cancer is not clear and indirect evidence
for endothelial ‘barrier’ effect was provided only for breast and
renal cell carcinomas (Griffioen et al, 1996; Reiss et al, 1998;
Bouma-ter Steege et al, 2004). Although previous histopathological
studies on specimens of human prostate carcinoma showed a
relatively rare involvement of malignant glands by lymphocytes
(Vesalainen et al, 1994; McArdle et al, 2004), the possible effects of
tumour neovasculature were not considered. To address this issue,
we related numbers of newly formed vessels in foci of carcinoma
and benign tissue to patterns and extent of leukcocyte infiltrates
assessed according to common and subset-specific markers. In
concordance with previous reports (Bono et al, 2002; Strohmeyer
et al, 2004), we detected increased numbers of microvessels in
the vicinity of malignant glands (Figure 1). Tissue-infiltrating
leukcocytes were found in both adenocarcinoma and NHPG
specimens; however, the malignant and benign prostate
tissues markedly differed in pattern of infiltration (Figure 2).
Although leukcocytes scattered diffusely throughout the tissue
were identified in foci of adenocarcinoma, adjacent benign tissue
and specimens affected by NHPG, leucocytes organised into
follicle-like clusters were barely detected in malignant tissue.
Because scattered leukcocytes could be found in prostate tissue
even in the absence of cancer, hyperplasia or florid prostatitis
(McClinton et al, 1990; Bostwick et al, 2003), we concluded that
scattered leucocytes unlikely represent tumour-directed immune-
effector cells. On the contrary, the differences in clustered
infiltrates between adenocarcinoma lesions, perimalignant tissue
and NHPG were not qualitative (irrespective of their location,
clusters were mainly composed of CD4 lymphocytes; Figure 3)
but rather quantitative (less intense clusters were detected in
malignant lesions; Figure 2), thereby implying a diminished access
of immune-effector cells to the tumour core. The diminished
involvement of malignant lesions by immune cells was associated
with augmented neoangiogenesis in the tumour site, as a negative
correlation between the extent of clustered infiltrate and values
of MVD was detected in foci of carcinoma but not in benign
perimalignant areas or NHPG specimens (Table 1). These findings
contribute to the hypothesis proposing a novel role for tumour
neovasculature in attenuation of lymphocyte extravasation and
strongly indicate the existence of endothelial ‘barrier’ phenomenon
in human prostate adenocarcinoma.
The molecular mechanism underlying endothelial ‘barrier’
phenomenon is not fully understood. Studies on murine melanona
and human breast carcinoma suggest that circulating lymphocytes
cannot properly interact with endothelial cells of neovessels
expressing diminished levels of CD54, CD106, CD62E and some
other CAMs (Dirkx et al, 2003; Bouma-ter Steege et al, 2004). In
our present study, we were able to detect only CD54 (but not
CD106 and CD62E) on prostate blood vessels (Figure 1), whereas
percentages of CD54-expressing vessels were significantly higher
in carcinoma specimens (in both adenocarcinoma foci and
perimalignant benign areas) than in NHPG specimens (Figure 1).
Intriguingly, a positive correlation between vascular CD54 and
percentage of tissue occupied by leucocyte infiltrate was demon-
strated only in benign prostate tissue but not in foci of carcinoma
(Table 1), thereby implying that this CAM contributes to
extravasation of lymphocyte in tissue not affected by malignant
transformation. Physiological significance of increased vascular
expression of CD54 in prostate carcinoma specimens is not clear.
It is noteworthy that, in murine hepatocellular carcinoma, an
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Figure 4 Expression of IL-10 in adenocarcinoma lesions (PAC), adjacent benign tissue (peri-PAC) and specimens of nodular hyperplasia of the prostate
gland (NHPG). (A) Typical pattern of IL-10 expression in malignant and benign prostate tissue (magnification  200). (B) Percentages of IL-10-expressing
specimens.
Impaired access of lymphocytes to neoplastic tissue
S Fedida et al
984
British Journal of Cancer (2007) 96(6), 980–985 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sincreased vascular expression of CD54 and CD106 was also
observed despite the fact that these neovessels were found to
inhibit extravasation of lymphocytes (Ryschich et al, 2006). The
latter study has also demonstrated that impaired interactions
between leukcocytes and vascular endothelium in this tumour
coincided with elevated expression of immune-suppressive cyto-
kine IL-10 by endothelial cells. In our study, IL-10 was detected in
most of adenocarcinoma lesions (Figure 4); however, we were
unable to rely IL-10 expression to leucocyte–endothelial interac-
tions, as functional approaches like intravital microscopy cannot
be applied to patients. It is tempting to speculate that circulating
lymphocytes are entrapped by CD54-expressing tumour neovessels
and become exposed to inhibitory cytokines (e.g. IL-10) and other
bioactive substances originating in the tumour site (Mantovani
et al, 2004).
We cannot exclude a possibility that CD54 expressed by prostate
neovasculature is also relevant for processes not directly related to
leucocyte–endothelial interactions. Recent reports implicate CD54
to cell signaling cascades involving Src and MAP family kinases
and cytoskeletal rearrangements (Wang et al, 2003; Kevil et al,
2004; Krunkosky and Jarrett, 2006). Therefore, elevated vascular
expression of CD54 could be an integral part of tumour-induced
‘angiogenic switch’ characterised by enhanced proliferation and
motility of endothelial cells. Further studies are required to test
this assumption.
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